pharmaphorum5y
Amgen/Allergan's rituximab biosimilar could be $4bn blockbuster
Data and analytics firm GlobalData said that the rituximab biosimilar, filed with the FDA ... Other drugs on the list include Bristol-Myers Squibb’s ozanimod (multiple sclerosis), Roche ...
pharmaphorum5y
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
If approved, Amgen and Allergan’s biosimilar – called ABP ... last month at a 10% discount to Roche’s US list price, initially only for Rituxan’s oncology indications as it has agreed ...
Hosted on MSN7mon
Dr Reddy’s Rituximab biosimilar Ituxredi gets EMA CHMP positive recommendation
The EMA CHMP has adopted a positive opinion recommending the launch of its proposed Rituximab biosimilar Ituxredi in European markets, the Hyderabad-based company said in a regulatory filing.
Morningstar1mon
Roche Emerging From Difficult Covid Comparisons With Solid Pharma and Diagnostics Prospects
Blockbuster cancer biologics Avastin, Rituxan, and Herceptin are seeing strong headwinds from biosimilars. However, Roche's biologics focus (more than 80% of pharmaceutical sales) provides some ...